SCHEMBL402248

SCHEMBL402248

COCOc1c(Br)cc(C(=O)OC)cc1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.56
PDK2 Q15119 1/20 0.39
EGFR P00533 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.37
SOS1 Q07889 1/20 0.36
TPMT P51580 1/20 0.36
LMNA P02545 4/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
HPGD P15428 1/20 0.35
CFTR P13569 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31573434 0.84 NOTUM (0.63) NOTUMPDK2SOS1TPMTLMNA
SCHEMBL400758 0.84 NOTUM (0.43) NOTUMEGFRMRGPRX4TPMTLMNA
SCHEMBL403251 0.82 NOTUM (0.42) NOTUMPDK2EGFRTPMTLMNA
SCHEMBL403025 0.80 ALDH1A1 (0.40) NOTUMEGFRTPMTLMNAMAPT
SCHEMBL10205503 0.79 SMN1; SMN2 (0.53) LMNAMAPTSMN1; SMN2HPGDMEN1
SCHEMBL8779698 0.77 EGFR (0.48) NOTUMEGFRLMNAMAPTCA12
SCHEMBL31573511 0.77 NOTUM (0.65) NOTUMPDK2SOS1LMNAMAPT
SCHEMBL399582 0.77 NOTUM (0.65) NOTUMPDK2SOS1LMNAMAPT
SCHEMBL22400332 0.77 NOTUM (0.69) NOTUMPDK2MRGPRX4SOS1LMNA
SCHEMBL29528597 0.77 NOTUM (0.69) NOTUMPDK2MRGPRX4SOS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
CN-101056628-B Ester derivatives and medicinal use thereof JAPAN TOBACCO INC 2011-05-25 CN disclosed
CN-101056628-A Ester derivatives and medicinal use thereof JAPAN TOBACCO INC (JP) 2007-10-17 CN disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA NOTUM 34/4885PDK2 2626/4885EGFR 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.